[Comparison of the efficacy of moricizine and disopyramide in the treatment of ventricular extrasystoles].

Abstract

Moricizine chlorhydrate (Ethmozine), a relatively unknown antiarrhythmic agent in France, is a derivative of Phenothiazine, related to the Vaughan-Williams Class IB drugs. A randomised, double-blind, crossover trial with Disopyramide 600 mg/day after a placebo period in 10 patients with ventricular extrasystoles, half of whom had underlying cardiac disease, showed that moricizine 750 mg/day significantly reduced (p less than 0.05) the overall number of ventricular extrasystoles by 81 +/- 46% (disopyramide 72 +/- 69%; NS) and that this drug is effective in 2/3 of patients by suppressing 70 to 100% of ventricular extrasystoles, whereas disopyramide was effective in only 40% of the same patients and never gave better results than Moricizine. Cardiac and extracardiac tolerance of Moricizine was good in this study, confirming previously reported results and its superiority when compared with disopyramide (20% of unwanted effects in this series).

• Authors: J P Fauchier, D Babuty, P Rouesnel, P Cosnay, J Estepo
• Journal: Archives des maladies du coeur et des vaisseaux (Arch Mal Coeur Vaiss) Vol. 84 Issue 4 Pg. 553-60 (Apr 1991) ISSN: 0003-9683 [Print] France
• Vernacular Title: Comparaison de l'efficacité de la moracizine et du disopyramide dans le traitement des extrasystoles ventriculaires.
• PMID: 1712193 (Publication Type: Clinical Trial, Comparative Study, English Abstract, Journal Article, Randomized Controlled Trial, Review)

Chemical References

• Placebos
• Moricizine
• Disopyramide

Topics

• Adolescent
• Adult
• Aged
• Cardiac Complexes, Premature (drug therapy)
• Disopyramide (therapeutic use)
• Double-Blind Method
• Electrocardiography, Ambulatory
• Female
• Heart Conduction System (drug effects)
• Heart Ventricles
• Humans
• Male
• Middle Aged
• Moricizine (pharmacology, therapeutic use)
• Placebos